Tuesday, October 27, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more

A U.S. judge rejected a bid to block ‌Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss

DO
By Daniel Okafor · Regulatory Correspondent
Oct 27 09:25 ETSource: STAT

From the source

STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more

A U.S. judge rejected a bid to block ‌Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss drugs

Read at statnews.com
PeptiPrescribed peptides from $99/moSee all →